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To determine the factors associated with an increased risk of developing varicella-zoster virus
(VZV) pneumonia during pregnancy, a case-control analysis was done in which 18 pregnant
women with VZV pneumonia were compared with 72 matched control subjects. VZV infection
was identified clinically, and VZV pneumonia was diagnosed by dyspnea and findings on chest
radiographs. Of 347 pregnant women with VZV infection, 18 (5.2%) had pneumonia treated
with acyclovir, and none died. Mean gestational age at rash onset was 25.8 ^ 8.8 weeks for
patients with pneumonia and 17.7 ^ 10.3 weeks for control subjects, which was not significant
in the multivariable model. Women with VZV pneumonia were significantly more likely to be
current smokers (odds ratio [OR], 5.1; 95% confidence interval [CI], 1.6– 16.7) and to have
>100 skin lesions (OR, 15.9; 95% CI, 1.9– 130.2). Pregnant women with VZV infection may
be more likely to develop varicella pneumonia if they are smokers or manifest >100 skin lesions.
Four million cases of varicella-zoster virus (VZV) infection
occurred annually in the United States during 1990–1994. Of
these cases, ,5% affected adults .20 years old, but 55% of
varicella-related deaths occurred in this older population [1].
Before the availability of varicella vaccine, varicella was estimat-
ed to cause 4000–11,000 hospitalizations and 100 deaths annually
in the United States alone [1]. The most common complication
of varicella in adults is pneumonia, usually caused by VZV alone,
but occasionally bacterial superinfection is implicated as well.
Before the advent of specific antiviral therapy, the mortality
rate of varicella pneumonia was 11.4%–15% for nonpregnant
adults [2, 3] and 36%–41% for pregnant women (retrospec-
tively reviewed in [3, 4]). After the advent of parenteral vidara-
bine and acyclovir (Acy) in 1983 to treat varicella pneumonia,
the maternal mortality rate declined to 13%–14% [4, 5]. This
decline has been attributed to the antiviral agents, better support-
ive intensive care, and earlier recognition and treatment.
Varicella pneumonia is so uncommon that large-scale studies
are very difficult to conduct. Most published studies represent
either collections of small case series or retrospective analyses
over many years. Consequently, risk factors for VZV pneumo-
nia in pregnant women have been difficult to identify. The re-
sults of 2 small English studies [6, 7] support the belief that
smoking is a risk factor for pneumonia in adults with varicella.
A noncontrolled retrospective analysis also supports this con-
clusion [8], and women in the third trimester appear to be at a
greater risk for developing VZV pneumonia [5]. Other possible
risk factors for VZV pneumonia in pregnant women are more
skin lesions at all stages [9] and the presence of pharyngeal var-
icella lesions.
The subjects in the present study were enrolled in a multisite
registry of VZV infection in pregnant women. The primary goal
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of the registry was to determine the risk of congenital varicella
syndrome and embryopathy caused by VZV. Here, we describe
the factors associated with varicella pneumonia in pregnant wom-
en and the outcomes of the 18 pregnancies.
Materials and Methods
Between March 1993 and March 1996, we enrolled 347 pregnant
women who contracted primary VZV infection during any trimes-
ter. We excluded from this analysis an additional 15 patients with
herpes zoster during pregnancy. The women were enrolled at 10
tertiary perinatal centers participating in the National Institute of
Child Health and Human Development Maternal-Fetal Medicine
Units Network, by use of a standard protocol.
Physicians in the geographic areas served by these tertiary cen-
ters referred patients for assessment and counseling when they de-
veloped a typical maculopapular rash with evolving vesicles and/
or pustules in a centripetal pattern. This clinical diagnosis of vari-
cella was accepted, since the disease is easy to identify. VZV iso-
lation was not required by the protocol. Patients were questioned
about previous episodes of varicella or herpes zoster, the source
and dates of exposure, and therapy with varicella-zoster immune
globulin (VZIG) or oral antiviral agents. They were asked about
initial symptoms of rash, fever, arthralgias, malaise, cough, and
dyspnea; later development of cough, fever, and dyspnea was re-
corded. Each patient also was asked about use of medications, etha-
nol, illegal drugs (e.g., cocaine, morphine, heroin, marijuana, hash-
ish, amphetamines, and methamphetamine) and cigarette smoking.
Chest radiographs were obtained for patients presenting with dys-
pnea or tachypnea. The diagnosis of varicella pneumonia was con-
firmed by visualization of interstitial infiltrates or nodular densities
in the lung fields.
Recorded physical characteristics included the patient’s highest
temperature during the illness, the anatomic areas involved with
the rash, and the physician’s estimate of total papulovesicular le-
sions at the peak of the rash (classified as ,100 or >100 lesions).
The dates of rash and of dyspnea onset and resolution were record-
ed from clinical study records or patient recall. When recall of de-
tails was uncertain, supporting medical records were sought.
All the women diagnosed with varicella pneumonia were en-
rolled in the study after the diagnosis was made. A disproportion-
ate number were enrolled at one center, so we selected 4 control
subjects with delivery information for each case patient, matched
by center and serology status.
After enrollment, the pregnant women were treated by their pri-
mary obstetrical care providers. Patients who met the diagnosis of
varicella pneumonia were treated by physicians in their own hos-
pital or at the tertiary referral center.
Categorical variables were analyzed by x2 and Fisher’s exact
tests. We used the Wilcoxon test for analysis of continuous vari-
ables. The baseline factors considered in the univariable analy-
sis—maternal age, third trimester rash onset (yes or no), vesicles
(,100 or >100), multiparous (yes or no), smoking during preg-
nancy, and drinking ethanol during the pregnancy—were used in
a multivariable logistic regression analysis to evaluate further the
relationship between the risk factors and VZV pneumonia. A
backward selection procedure was used, whereby the least signifi-
cant term was removed and the model was refitted. The result was
checked with a forward selection process. Adjusted odds ratios
(ORs) and 95% confidence intervals (CIs) then were computed.
P , :05 was considered to be significant.
Results
Of the 18 women with varicella pneumonia, as defined by dys-
pnea and a positive chest radiograph, none were lost to follow-up.
Two other women with chest radiographic findings of typical
changes of interstitial pneumonitis were excluded because of
lack of dyspnea or tachypnea.
The racial composition of the study population (18 case pa-
tients and 72 control subjects) was as follows: black, 37 (41.1%)
women; Asian descent, 2 (2.2%) women; white, 46 (51.1%) wom-
en; and Hispanic, 5 (5.6%) women. At enrollment, 34 women
(37.8%) worked outside the home. The source of varicella was
a related child in 46 (51.1%) cases, an unrelated child in 15
(16.7%) cases, the pupil of a pregnant teacher in 2 (2.2%) cases,
and not certain in 27 (30.0%) cases.
Table 1 shows the demographic and medical factors tested in
a univariable analysis for an association with an increased like-
lihood of developing varicella pneumonia. There was no signifi-
cant difference with respect to maternal age, race, use of illegal
drugs, or drinking ethanol during pregnancy between the 18
women who developed varicella pneumonia and the 72 women
who did not. VZIG use was inconsistent in the study population,
with only 3 (17%) of 18 case patients and 7 (9.7%) of 72 control






(n = 72) OR (95% CI)
Maternal age,
mean years ^ SDa 25.7 ^ 4.9 24.7 ^ 5.1
Black race 7 (39) 30 (42) 0.9 (0.3–2.6)
Multiparous 15 (83) 46 (64) 2.8 (0.7–10.7)
Ever smoked 13 (72) 28 (39) 4.1 (1.3–12.7)
Current smoker 11 (61) 16 (22) 5.5 (1.8–16.5)b
Current EtOH drinker 7 (39) 22 (31) 1.4 (0.5–4.2)
Illegal drugs 4 (22) 6 (8.3) 3.1 (0.8–12.6)
GA at rash onset,
mean weeks ^ SDc 25.8 ^ 8.8 17.7 ^ 10.3
Rash onset at
third trimesterd 10 (56) 17 (24) 4.0 (1.4–11.9)
>100 Vesiclese 17 (94) 36 (50) 17.0 (2.1–134.6)
NOTE. Data are no. (%) of patients, except where noted. CI, confidence
interval; GA, gestational age; EtOH, ethanol; OR, odds ratio.
a P ¼ :46.
b Adjusted OR, 5.1 (95% CI, 1.6–16.7), by multivariable logistic regression
analysis.
c P ¼ :0044. Not significant by multivariable logistic regression analysis.
d Not significant by multivariable logistic regression analysis.
e Adjusted OR, 15.9 (95% CI, 1.9–130.2), by multivariable logistic regres-
sion analysis.
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subjects receiving VZIG after exposure (table 2). Of the 10
women given VZIG, only 1 of 3 case patients and 5 of 7 control
subjects received it within the recommended 96-h window after
exposure to VZV, so no conclusions could be drawn from those
data. Women with varicella pneumonia were significantly more
likely to have developed varicella at a later gestational age.
Pregnant women with varicella pneumonia were more likely
to be current smokers. Of the 18 women with symptomatic vari-
cella pneumonia, 17 had >100 skin lesions typical of varicella.
There was no significant difference between the 2 groups in the
location or distribution of the lesions (data not shown).
Among 18 patients with varicella pneumonia, the onset of the
rash occurred during the first 13 weeks of pregnancy (first tri-
mester) in 2 cases (11%), during the second 13 weeks (second
trimester) in 6 cases (33%), and at >26 weeks of gestation
(third trimester) in 10 cases (56%) (table 2). In contrast, of 72
women without varicella pneumonia who developed a varicella
rash, 35 (48.6%) did so in the first trimester, 18 (25%) did so in
the second trimester, and 19 (26.4%) did so in the third trimes-
ter. The multivariable logistic regression analysis (table 1)
showed only 2 factors significantly correlated with an increased
chance of varicella pneumonia: >100 skin lesions (OR, 15.9;
95% CI, 1.9–130.2) and smoking during the affected pregnancy
(OR, 5.1; 95% CI, 1.6–16.7).
Among the 18 women with varicella pneumonia, the median
incubation interval between exposure and onset of the rash was
13 days (range, 7–23 days) in the 16 case patients with known
exposure; for 2 case patients, the source was unknown. The me-
dian interval between the onset of rash and diagnosis of varicella
pneumonia was 3 days (range, 0–6 days); 4 women presented
with dyspnea on the day the rash appeared. The median duration
of dyspnea was 5.5 days (range, 1–85 days) in the 14 women
for whom the date of resolution was recorded. In the single case
of known duration in the first trimester, dyspnea lasted 4 days.
The median duration of dyspnea was 6.5 days (range, 1–85 days)
in the 6 second-trimester cases and 5 days (range, 1–24 days)
in 7 of 10 third-trimester cases.
Intravenous Acy therapy was initiated at a dose of 5–15 mg/kg
of body weight every 8 h on the day that varicella pneumonia was
diagnosed in 11 cases, 1 day after diagnosis in 5 cases, 2 days
after diagnosis in 1 case, and 3 days after diagnosis in 1 case.
The dose of intravenous Acy administered was not subject to
the protocol and was determined by the responsible physician(s)
at each tertiary center. Table 2 shows the daily dose of intra-
venous Acy used for 16 of 18 women treated; the median dose
was 800 mg per day in 3 divided doses. The exact dose was not
available for 2 women. Because of the unknown safety of oral
Acy during pregnancy and its uncertain benefits during the study
period in 1993–1996, neither case patients nor control subjects
were treated with oral Acy before the diagnosis of varicella
pneumonia.
Table 3 shows the outcomes of the 18 pregnancies. One wom-
an developed a rash at 24 weeks, vaginally delivered a 710-g
stillborn baby at 25 weeks of gestation, and developed varicella
















1 38 4 0 940 Missing
2 32 3 1 800 6
3 10 2 2 900 Missing
4 (15)b 21 2 0 2182 15
5 5 3 0 1250 4
6 36 4 1 1300 Missing
7 (3)b 27 0 0 1350 5
8 21 0 0 800 6
9 28 1 0 500 4
10 16 4 1 1000 0
11 26 3 1 800 Missing
12 23 4 1 1000 3
13 26 0 3 300 24
14 (15)b 23 3 0 Missing 7
15 24 6 0 600 85
16 35 4 0 800 1
17 34 6 0 650 8
18 32 3 0 Missing 4
NOTE. GA, gestational age.
a The duration of dyspnea was not known in 4 cases because the date of resolution was not recorded.
b Received varicella-zoster immune globulin (VZIG). No. in parentheses is the interval (days) between exposure and VZIG
injection.
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pneumonia on the first postpartum day. The other 17 infants
were delivered at gestational ages at or beyond 36 4/7 weeks
with no evidence of neonatal varicella. Another patient devel-
oped varicella rash at 36 2/7 weeks of gestation and presented
with severe respiratory failure 4 days later. After intravenous
Acy was started at 15 mg/kg of body weight every 8 h, an endo-
tracheal tube was placed for mechanical ventilation, and her
condition worsened. For that reason, the 3266-g infant was de-
livered by low-transverse cesarean section. The mother recov-
ered without sequelae after 7 days of intravenous Acy therapy.
The infant was treated with VZIG and Acy and recovered with-
out evidence of morbidity from VZV.
For the 18 study women, delivery was vaginal in 12 cases, in-
cluding 2 low forceps deliveries, and cesarean in 6 cases. Five
cesarean deliveries were performed for obstetrical indications
and 1 (mentioned above) for acute maternal respiratory failure.
Postpartum morbidity in the 18 women included cortical venous
thrombosis in 1 after cesarean delivery 45 days after varicella
pneumonia. Another woman, who was intubated and received
mechanical ventilation for 6 weeks because of bacterial superin-
fection, had only 40% of the expected values on pulmonary
function tests at the onset of her next pregnancy 1 year later.
None of these 18 cases resulted in maternal death (95% CI,
0%–17.6%).
Discussion
The frequency of varicella pneumonia has been difficult to
determine in most populations. The incidence has been reported
as 1 in 2000 to 1 in 10,000 pregnancies [10, 11]. Only 8 cases of
varicella pneumonia (1.3/10,000 pregnancies) were reported
in the 60,000 pregnancies studied during 1959–1965 in the Col-
laborative Perinatal Project [12], but these data from 35 years
ago are not applicable to the present. The frequency of varicella
in all adults was estimated to be 1.2–4.5/100,000 hospital ad-
missions in Stockholm during 1980–1989 [13] and 6/100,000
in Scotland during 1989–1990 [14]. Miller et al. [14] reported
an increasing frequency of varicella in adults in England and
Wales over the past 2 decades, and a recent upward shift in the
age distribution of varicella has been reported in the United
States [15]. Although the reasons for such changes in age distri-
bution are complex, they could herald more frequent encoun-
ters between pregnant women and varicella pneumonia. On the
other hand, the advent of extensive varicella vaccination may
decrease this hazard appreciably.
The diagnosis of varicella in the pregnant women in this study
was made by clinical identification of the typical rash. With re-
spect to radiographic diagnostic criteria for varicella pneumo-
nia, a report of 110 chest radiographs in 114 US Army recruits
who developed varicella during basic training showed that 18
(16.3%) had interstitial and/or nodular infiltrates indicative
of pneumonia. Only 4 of those 18, however, complained of a
“dry, nonproductive cough” and only 2 (11.1%) complained
of dyspnea [16]. In our study group, 68 (20.7%) of 329 pregnant
women with varicella but no radiologic evidence of pneumonia
also reported dyspnea. These findings could be explained by the
pregnancy itself, since pregnant women occasionally feel dys-
pneic even when they do not have varicella or any other respira-
tory infection. In a retrospective emergency room study of 130
adults affected by varicella, dyspnea occurred in 7.7% of 117








weight, g Mode of delivery
GA at
delivery, weeks
1 38 10 3013 Low forceps 40
2 32 45 3232 Cesarean 39
3 10 207 3410 Spontaneous vaginal 39
4 21 127 3033 Cesarean 40
5 5 238 3730 Cesarean 40
6 36 2 3266 Cesarean 37
7 27 101 3714 Spontaneous vaginal 41
8 21 113 2989 Spontaneous vaginal 37
9 28 78 3490 Spontaneous vaginal 39
10 16 153 3080 Cesarean 38
11 26 75 2810 Spontaneous vaginal 37
12 23 110 3005 Spontaneous vaginal 39
13 26 94 2962 Cesarean 39
14 23 115 2270 Spontaneous vaginal 40
15 24 1 710 Spontaneous vaginal 25
16 35 112 2225 Low forceps 36
17 34 33 3770 Low forceps 40
18 32 43 2807 Spontaneous vaginal 38
NOTE. The only fetal death was the child of subject 15; all others were born alive. GA, gestational age.
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patients with normal chest radiographs and in 61.5% of the 13
patients with radiographic evidence of pneumonia [17]. These
results support the belief that radiologic changes alone do not
predict clinically significant pneumonia requiring treatment.
For that reason and because a chest radiograph immediately
after rash onset might not detect later development of varicella
pneumonia, routine chest radiographs are not warranted for all
pregnant women who develop varicella.
This study was not designed to evaluate varicella pneumonia
therapy and, therefore, contained no guidelines to standardize
the therapy, as shown by the variation in daily doses of intrave-
nous Acy. Previous case series of maternal varicella pneumonia
reported a case-fatality rate of 36%–41% before the introduc-
tion of specific antiviral agents such as Acy [3, 4]. Reports since
the advent of Acy therapy still indicate a maternal mortality
rate of 13%–14% [4, 5]. The lack of maternal mortality in our 18
cases probably represents the result of early diagnosis and vigor-
ous antiviral drug treatment but could be merely fortuitous.
Only 10 (11%) of 90 exposed pregnant women were given VZIG
after exposure to a varicella source contact, and only 6 of these
10 women received VZIG within 96 h after exposure. This find-
ing strongly suggests the need for education of physicians and
antepartum patients to improve the appropriate use of this pro-
tective preparation.
We identified a history of smoking as a significant feature of
pregnant women with pneumonia when they contracted varicel-
la (OR, 5.1; 95% CI, 1.6–16.7). This finding is consistent with
earlier reports in the literature [6–8], although the previous stud-
ies also involved adult men and nonpregnant women. Of 29
adults admitted to the hospital in Manchester, United Kingdom
[6], 7 (37%) of 19 smokers (only 1 pregnant woman) developed
varicella pneumonia, compared with none of 10 nonsmokers
(P ¼ :032). Among 67 immunocompetent adults described else-
where [7], 16 (47%) of 34 smokers developed varicella pneumo-
nia, compared with 1 of 33 nonsmokers. In a series of emergency
room patients between 1979–1987, 7 (64%) of 11 adults treated
early for varicella pneumonia and 20 (74%) of 27 adults not treat-
ed with Acy reported smoking, but the comparison group was
merely the overall smoking rate of 30% in the region during
that time [8]. Similarly, 11 of 13 women treated in the United
Kingdom with Acy for varicella pneumonia were smokers, but
no comparison figure was provided [18].
Other reported risk factors for varicella pneumonia include
the trimester of rash onset. The case series of Acy therapy re-
ported by Smego and Asperilla [5] revealed no maternal deaths
among 12 women with varicella in the second trimester, but 3
of 9 women who developed varicella during the third trimester
died of pneumonia and complications. In a different collection
of case series including 28 pregnant women affected by varicel-
la pneumonia, 3 women were in the second trimester and 21
were in the third trimester [19]. Four of the women in the latter
report had an unknown gestational age, and there were 3 ma-
ternal deaths (10.7%), but the gestational age of only 1 of the 3
was specified (30 weeks). Compared with these heterogeneous
mixtures of case series, gestational age and trimester of onset
appeared to be significant factors in our study as well, but these
gestational age factors dropped from the multivariable model.
A higher number of skin lesions has been reported to be as-
sociated with greater frequency of varicella pneumonia [9], but
the findings of an Australian study did not support that conclu-
sion [20]. In the present study, we found a significantly greater
proportion (94.4%) of patients with varicella pneumonia af-
flicted with >100 skin lesions than control subjects (50.0%), and
this factor remained significant in the multivariable model (OR,
15.9; 95% CI, 1.9–130.2). Our data support the concept that iden-
tifying more lesions increases the risk of developing varicella
pneumonia, perhaps because of a greater virus load during viremia.
In view of the high maternal mortality rate of varicella pneumo-
nia, however, there is a significant hazard in using this arbitrary
estimate to delay vigorous diagnostic approaches to women with
,100 skin lesions at first examination. For a pregnant woman
with dyspnea or tachypnea, waiting for 100 skin lesions to ap-
pear before obtaining a chest radiograph or an arterial blood gas
reading or starting intravenous antiviral therapy would be unwise.
Our demographic and medical information for 18 pregnant
women with varicella pneumonia provide meaningful contem-
porary data on a rare complication of a common childhood
disease. Because of the standardized data collection method,
information about maternal age, gravidity, parity, gestational
age at the onset of rash, smoking history, number of maternal
skin lesions, and peak temperature, we could determine statis-
tically significant features associated with an increased likeli-
hood of developing varicella pneumonia. Physicians caring
for pregnant women who contract varicella may use these find-
ings to formulate management plans that will permit earlier
recognition of varicella pneumonia and earlier therapy with in-
travenous Acy.
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